UBS strongly resets Lilly stock target
UBS strongly resets Lilly stock target.
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Eli Lilly ( LLY ) has seen a lot of bullish calls from Wall Street in July.
Guggenheim , Truist , Bank of America , Bernstein , and JPMorgan all raised their price targets in the first half of the month.
UBS's call is worth watching closely because it landed in the same week as prescription data that point in a bearish direction .
For anyone holding Lilly stock into its August earnings report, the gap between those two things is worth looking at.
On July 13 , UBS analyst Michael Yee lifted his price target on Eli Lilly to $1,425 from $1,250 and kept a buy rating.
That is a 14% increase from the previous target, and it implies a roughly 20% boost from where the stock traded on the July 13.
Jim Cramer crowns one surging sector the hottest in the market
Yee tied the raise to sales momentum in Mounjaro and Zepbound , Lilly's diabetes and obesity injections. He also cited optimism around Kisunla , its Alzheimer's treatment, Financial Modeling Prep reported.
A buy rating means the analyst expects the stock to outperform . The $1,425 figure is where he thinks shares could trade over the next 12 months.
UBS was not alone. Guggenheim moved to $1,273 , BofA to $1,334 , Truist to $1,370 , and Bernstein to $1,385 , all in the same stretch, according to GuruFocus .
The bull case rests on a business that has been growing at a pace that's rare for major pharmaceutical companies.
In the first quarter of 2026 , revenue rose 56% to $19.8 billion , and Lilly raised full-year guidance to between $82 billion and $85 billion , Lilly 's earnings release showed.
Mounjaro brought in $8.66 billion worldwide, more than doubling from the same quarter in 2025.
U.S. revenue climbed 43% to $12.1 billion on a 49% jump in volume.
Adjusted earnings came to $8.55 per share against a $6.66 consensus, CNBC reported.
Volume did that work, not price. Realized prices fell in both markets, and demand still overwhelmed the drag.
That is the pattern Lilly's management promised, and it is the reason analysts keep moving their targets up.
